Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics, Inc. (ATXS)
NASDAQ:ATXS
ATXS Stock Chart & Stats
$12.58
-$0.31(-3.58%)
At close: 4:00 PM EST
$12.58
-$0.31(-3.58%)
Day’s Range― - ―
52-Week Range$3.56 - $13.29
Previous CloseN/A
Volume35.54K
Average Volume (3M)735.53K
Market Cap
$718.13M
Enterprise Value$626.31M
Total Cash (Recent Filing)$227.72M
Total Debt (Recent Filing)$4.46M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Mar 05, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding57,084,840
10 Day Avg. Volume814,501
30 Day Avg. Volume735,535
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-6.16
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue887.12
Enterprise Value/Gross Profit887.12
Enterprise Value/Ebitda-4.67
Forecast
1Y Price Target
$13.00Price Target Upside3.34% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition ValuationAnalyst notes the agreed cash-and-stock acquisition values Astria at $13 per share, representing about a 53% premium to the prior closing price and offering immediate value uplift for Astria shareholders.
Clinical Profile And DosingAnalyst highlights that navenibart's Phase 3 status and long‑acting dosing every three to six months could significantly reduce injection and visit burden, encouraging patient switches from current therapies.
Commercial FitAnalyst states BioCryst's established commercialization infrastructure and existing hereditary angioedema oral therapy create a complementary oral plus long‑acting injectable strategy that could maximize navenibart's market penetration.
Bears Say
Deal Execution RiskAnalyst rescinded the price target and moved to Perform pending the anticipated transaction close in 1Q26, indicating execution and regulatory uncertainty until the deal completes.
Pipeline ReprioritizationAnalyst notes BioCryst intends to seek strategic alternatives for STAR‑0310 because it does not fit the rare disease strategy, which could reduce the combined company's pipeline diversification.
Valuation OutlookAnalyst moved the rating to Market Perform based on the current share price versus the acquisition price, signaling limited near-term upside for investors.
Astria Therapeutics News
ATXS FAQ
What was Astria Therapeutics, Inc.’s price range in the past 12 months?
Astria Therapeutics, Inc. lowest stock price was $3.56 and its highest was $13.29 in the past 12 months.
What is Astria Therapeutics, Inc.’s market cap?
Astria Therapeutics, Inc.’s market cap is $718.13M.
When is Astria Therapeutics, Inc.’s upcoming earnings report date?
Astria Therapeutics, Inc.’s upcoming earnings report date is Mar 05, 2026 which is in 35 days.
How were Astria Therapeutics, Inc.’s earnings last quarter?
Astria Therapeutics, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.159.
Is Astria Therapeutics, Inc. overvalued?
According to Wall Street analysts Astria Therapeutics, Inc.’s price is currently Undervalued.
Does Astria Therapeutics, Inc. pay dividends?
Astria Therapeutics, Inc. does not currently pay dividends.
What is Astria Therapeutics, Inc.’s EPS estimate?
Astria Therapeutics, Inc.’s EPS estimate is -0.54.
How many shares outstanding does Astria Therapeutics, Inc. have?
Astria Therapeutics, Inc. has 57,084,840 shares outstanding.
What happened to Astria Therapeutics, Inc.’s price movement after its last earnings report?
Astria Therapeutics, Inc. reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went up 0.32%.
Which hedge fund is a major shareholder of Astria Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ATXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Astria Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.00 (3.34% Upside)
$13.00 (3.34% Upside)
Blogger Sentiment
Bullish
ATXS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.95%
12-Months-Change
Fundamentals
Return on Equity
-43.15%
Trailing 12-Months
Asset Growth
-24.82%
Trailing 12-Months
Company Description
Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
ATXS Stock 12 Month Forecast
Average Price Target
$13.00
▲(3.34% Upside)
Technical Analysis
Autolus Therapeutics
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
PureTech Health
―
Monte Rosa Therapeutics
―
Ownership Overview
Currently, No data available
---